GoAI
Get started
CorMedix Inc. logo

CorMedix Inc.

CRMD

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$8.20

−$0.03 · -0.36%

Aug 21, 4:00 PM ET

CRMD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

87

Deep Value

Momentum

42

Neutral

Sentiment

66

Bullish

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Joseph Todisco
Listed since
May 13, 2010
Employees
191

Market position

Day range

Current $8.20

52-week range

Current $8.20

Open
$8.29
Previous close
$8.23
Volume
1.5M
1.14× average
Average volume
1.31M
Average daily volume
Market cap
643.31M USD
Beta
1.5
Market reference 1
50-day average
$8.0896
+1.36% above average
200-day average
$8.3861
-2.22% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
840.84M USD
P/E (TTM)
3.4×
P/B (TTM)
1.4×
P/S (TTM)
1.39×
EV / EBITDA
5.01×
Earnings yield
19.46%
Free cash flow yield
20.62%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
82.78%
Operating margin
46.95%
Net margin
40.49%
Return on equity
40.23%
Return on assets
19.74%
Return on invested capital
22.98%

Financial health

Debt / equity
0.31×
Current ratio
2.11×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends4786%-13980%-32746%-51511%Gross margin, FY2021: 22.00%Gross margin, FY2022: 94.29%Gross margin, FY2024: 92.66%Gross margin, FY2025: 88.46%Operating margin, FY2021: -15417.51%Operating margin, FY2022: -46819.91%Operating margin, FY2024: -51.43%Operating margin, FY2025: 48.17%Net margin, FY2021: -14774.70%Net margin, FY2022: -45409.90%Net margin, FY2024: -41.24%Net margin, FY2025: 52.31%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 22.00%. Gross margin FY2022 94.29%. Gross margin FY2024 92.66%. Gross margin FY2025 88.46%. Operating margin FY2021 -15417.51%. Operating margin FY2022 -46819.91%. Operating margin FY2024 -51.43%. Operating margin FY2025 48.17%. Net margin FY2021 -14774.70%. Net margin FY2022 -45409.90%. Net margin FY2024 -41.24%. Net margin FY2025 52.31%.

Income trends

Revenue

311.71M USD+617.03%

Operating income

150.14M USD+172.5M USD

Net income

163.06M USD+180.99M USD
Income trends across reported periods347.78M USD203.51M USD59.24M USD−85.02M USDRevenue, FY2021: 190.94K USDRevenue, FY2022: 65.41K USDRevenue, FY2024: 43.47M USDRevenue, FY2025: 311.71M USDOperating income, FY2021: −29.44M USDOperating income, FY2022: −30.62M USDOperating income, FY2023: −48.96M USDOperating income, FY2024: −22.36M USDOperating income, FY2025: 150.14M USDNet income, FY2021: −28.21M USDNet income, FY2022: −29.7M USDNet income, FY2023: −46.34M USDNet income, FY2024: −17.93M USDNet income, FY2025: 163.06M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 190.94K USD. Revenue FY2022 65.41K USD. Revenue FY2024 43.47M USD. Revenue FY2025 311.71M USD. Operating income FY2021 −29.44M USD. Operating income FY2022 −30.62M USD. Operating income FY2023 −48.96M USD. Operating income FY2024 −22.36M USD. Operating income FY2025 150.14M USD. Net income FY2021 −28.21M USD. Net income FY2022 −29.7M USD. Net income FY2023 −46.34M USD. Net income FY2024 −17.93M USD. Net income FY2025 163.06M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue311.71M USD43.47M USD—65.41K USD190.94K USD
Cost of goods sold35.96M USD3.19M USD205.56K USD3.73K USD148.94K USD
Gross profit275.75M USD40.28M USD−205.56K USD61.67K USD42K USD
Research and development19.33M USD3.94M USD13.16M USD10.68M USD13.13M USD
Selling, general, and administrative30.17M USD58.7M USD35.8M USD20.01M USD16.35M USD
Operating expenses125.61M USD62.64M USD48.75M USD30.69M USD29.48M USD
Interest income3.85M USD2.58M USD2.68M USD326.02K USD14.4K USD
Interest expense2.78M USD36.41K USD34.3K USD26.52K USD15.94K USD
Depreciation and amortization14.99M USD309.78K USD70.76K USD209.04K USD177.02K USD
Operating income150.14M USD−22.36M USD−48.96M USD−30.62M USD−29.44M USD
Net income163.06M USD−17.93M USD−46.34M USD−29.7M USD−28.21M USD

Company facts updated Aug 24, 2026.

CRMD peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CRMD

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
16.77M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
15.71M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Avantis U.S. Small Cap Value ETF logoAvantis U.S. Small Cap Value ETFAVUV
Market value
11.3M
Weight
0.04%
AUM
31.27B USD
Expense ratio
0.25%
Price / 1D
$126.45+0.66%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
6.3M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
5.59M
Weight
0.04%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
5.52M
Weight
0.98%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$72.80+0.71%
Pacer US Small Cap Cash Cows ETF logoPacer US Small Cap Cash Cows ETFCALF
Market value
5.18M
Weight
0.13%
AUM
3.89B USD
Expense ratio
0.59%
Price / 1D
$57.80+0.87%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.15M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research CRMD

research.disclaimer